The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Figure 6

dBET57 treatment downregulates the superenhancer-related gene ZMYND8 in NB. (a) RNA-seq volcanic map of dBET57. (b) Heat map of differentially expressed genes (, ) in SK-N-BE(2) cells treated with 1200 nM dBET57, each column represents a sample, each row represents a gene, blue represents gene downregulation, and red represents gene upregulation. (c) ZMYND8 protein level decreased in a gradient-dependent manner with dBET57 concentration. (d) The IGV diagram shows the CHIP-seq spectrum of downstream indicator genes. (e) Tumor profile of ZMYND8-specific expression (CCLE). (f) Expression of ZMYND8 in NB and NC cells. value was determined by unpaired two-sided -test. (g) The prognosis of ZMYND8. value was determined by log-rank test. (h) ZMYND8 mRNA and protein expression level in SK-N-BE(2) cell. (i) Cell proliferation ability of sh-NC and sh-ZMYND8. (j) Clonogenic ability of sh-NC and sh-ZMYND8. Scale bars: 4 mm. (k) Apoptosis ability of sh-NC and sh-ZMYND8. (l) Cellular distribution of sh-NC and sh-ZMYND8. Each sh-ZMYND8 group was compared with the sh-NC group. , , and ; ns: not significant.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)